For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ.
Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and the possible damage of an immunosuppressive or cytotoxic drug. The problem with the immunosuppressive drugs for transplant that we commonly use today is that they not only have the desired effect of suppressing the immune system, but they also have undesirable side effects such as high blood pressure, high cholesterol, kidney toxicity and diabetes. Unfortunately, these drugs are powerful and can affect your whole body instead of just the immune response to your transplanted organ.
The good news is that although these drugs can have serious side effects, they are much easier to cope with than they once were. Immunosuppressive drugs for transplant are of great value in treatment for organ transplant recipients by helping to prolong life, preserve function, reduce symptoms, and sometimes may serve to put the disease into remission.
Now more than ever, there is a need to for extensive research and development in the immunology research field to accomplish the following:
• Develop new immunosuppressive drugs which minimize the toxicity and side effects of therapy
• Reduce the number of medications patients must take to prevent rejection, including reducing steroid use
• Create immune tolerance to the transplant to totally eliminate the need for use of immunosuppressive medications
Currently, the following Immunosuppressant products are available from LGM Pharma
, (a US based API supplier) for R&D purposes:
Inquire today about Immunosuppressive product prices, DMF, GMP, cGMP, delivery, purity and more.
*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.